CYP1A2 and ADORA2A Genotypes and Endurance Performance.

Launched by MASARYK UNIVERSITY · Aug 7, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how certain genes might affect how well people perform after taking caffeine. The researchers want to find out if variations in two specific genes, CYP1A2 and ADORA2A, can influence endurance performance, like how long someone can exercise on a stationary bike after consuming caffeine. The trial is currently recruiting healthy individuals aged between 65 to 74 years old, and anyone can join regardless of their fitness level, as long as they meet some basic health criteria.

To participate, you should be a healthy adult who can safely ride a stationary bike and doesn’t have any health issues like heart disease or high blood pressure. You should not be pregnant, breastfeeding, or recently ill, and you shouldn’t have taken caffeine during the study period. If you join, you can expect to take part in a controlled test where some participants receive caffeine, while others receive a placebo (a substance with no active effect), and then assess how it affects your endurance performance. This trial is a great opportunity to contribute to understanding how our genes can influence our physical abilities!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • healthy person
• • any training status
• • within age limits
• • without contraindications to perform the test on a bicycle trainer
• • No contraindications to caffeine intake
• Exclusion Criteria:
• • Pregnancy
• • Breast feeding
• • Cardiovascular disease
• • Hypertension
• • Liver disease in the previous two months
• • Taking drugs that can affect liver function
• • Illness in the period of 14 days before the start of the research
• • Use of caffeine during research